
30/08/2025
' In diseases such as , amyotrophic lateral sclerosis and , sustained perpetuated by activated microglia is a hallmark feature. Moreover, in symptoms, inflammatory mechanisms are also likely to play a substantial role. '
' extracts are used as an accepted treatment option for and indications in different countries as well as for ameliorating cognitive impairment and quality of life in dementia sufferers. a number of different pharmacological activities with potential relevance for the clinical use have been reported from clinical and non-clinical studies, including vasoregulatory activity, improved blood flow, antioxidative activity, reduction in amyloid oligomer and plaque formation and toxicity, improvement of neuroplasticity, increase in neurotransmitter levels and protection against mitochondrial dysfunction. a standardised extract of Ginkgo biloba leaves is a well defined product and contains approximately 24% flavone glycosides (primarily quercetin, kaempferol and isorhamnetin) and 6% terpene lactones (2.8-3.4% ginkgolides A, B and C, and 2.6-3.2% bilobalide). Ginkgolide B and bilobalide account for about 0.8% and 3% of the total extract, respectively. other constituents include proanthocyanadins, glucose, rhamnose, organic acids, D-glucaric and ginkgolic acids. '
Badanjak, K.; Fixemer, S.; Smaji, S.; Skupin, A.; Grünewald, A. The Contribution of Microglia to Neuroinflammation in Parkinson’s Disease. Int. J. Mol. Sci. 2021, 22, 4676.
Thakur, S.; Dhapola, R.; Sarma, P.; Medhi, B.; Reddy, D.H. Neuroinflammation in Alzheimer s Disease: Current Progress in Molecular Signaling and Therapeutics. Inflammation 2023, 46, 1–17.
Merad, M.; Blish, C.A.; Sallusto, F.; Iwasaki, A. The Immunology and Immunopathology of COVID-19. Science 2022, 375, 1122–1127.
Nalbandian, A.; Sehgal, K.; Gupta, A.; Madhavan, M.V.; McGroder, C.; Stevens, J.S.; Cook, J.R.; Nordvig, A.S.; Shalev, D.; Sehrawat, T.S.; et al. Post-Acute COVID-19 Syndrome. Nat. Med. 2021, 27, 601–615.
Huang, S.Y.; Jeng, C.; Kao, S.C.; Yu, J.J.H.; Liu, D.Z. Improved Haemorrheological Properties by Ginkgo Biloba Extract (Egb 761) in Type 2 Diabetes Mellitus Complicated with Retinopathy. Clin. Nutr. 2004, 23, 615–621.
Kellermann, A.J.; Kloft, C. Is There a Risk of Bleeding Associated with Standardized Ginkgo Biloba Extract Therapy? A Systematic Review and Meta-Analysis. Pharmacotherapy 2011, 31, 490–502.
Abdel-Wahab, B.A.; Abd El-Aziz, S.M. Ginkgo Biloba Protects against Intermittent Hypoxia-Induced Memory Deficits and Hippocampal DNA Damage in Rats. Phytomedicine 2012, 19, 444–450.
Luo, Y.; Smith, J.V.; Paramasivam, V.; Burdick, A.; Curry, K.J.; Buford, J.P.; Khan, I.; Netzer, W.J.; Xu, H.; Butko, P. Inhibition of Amyloid-Beta Aggregation and Caspase-3 Activation by the Ginkgo Biloba Extract EGb761. Proc. Natl. Acad. Sci. USA 2002, 99, 12197–12202.
Tchantchou, F.; Xu, Y.; Wu, Y.; Christen, Y.; Luo, Y. EGb 761 Enhances Adult Hippocampal Neurogenesis and Phosphorylation of CREB in Transgenic Mouse Model of Alzheimer’s Disease. FASEB J. 2007, 21, 2400–2408.
Kehr, J.; Yosh*take, S.; Ijiri, S.; Koch, E.; Nöldner, M.; Yosh*take, T. Ginkgo Biloba Leaf Extract (EGb 761®) and Its Specific Acylated Flavonol Constituents Increase Dopamine and Acetylcholine Levels in the Rat Medial Prefrontal Cortex: Possible Implications for the Cognitive Enhancing Properties of EGb 761®. Int. Psychogeriatr. 2012, 24 (Suppl. 1), S25–S34.
Abdel-Kader, R.; Hauptmann, S.; Keil, U.; Scherping, I.; Leuner, K.; Eckert, A.; Müller, W.E. Stabilization of Mitochondrial Function by Ginkgo Biloba Extract (EGb 761). Pharmacol. Res. 2007, 56, 493–502.